Abstract
Cell movement and adhesion serve critical roles in a wide variety of physiological situations, and when dysregulated can contribute to the pathogenesis of many diseases. Recently, Lyn kinase has emerged as a crucial regulator of ‘inside-out’ integrin signaling in hematopoietic cells, that when dysregulated, can lead to the development of an “invasive cell” phenotype in a variety of pathological contexts ranging from leukemia to neuro-inflammatory disorders. Here, we discuss several pathologies associated with perturbations of Lyn-dependent inside-out integrin signaling pathways in blood cells.
Current Signal Transduction Therapy
Title: The Novel Role for Lyn in Integrin Signaling in Human Disease
Volume: 4 Issue: 1
Author(s): Brian Tomkowicz and Andrzej Ptasznik
Affiliation:
Abstract: Cell movement and adhesion serve critical roles in a wide variety of physiological situations, and when dysregulated can contribute to the pathogenesis of many diseases. Recently, Lyn kinase has emerged as a crucial regulator of ‘inside-out’ integrin signaling in hematopoietic cells, that when dysregulated, can lead to the development of an “invasive cell” phenotype in a variety of pathological contexts ranging from leukemia to neuro-inflammatory disorders. Here, we discuss several pathologies associated with perturbations of Lyn-dependent inside-out integrin signaling pathways in blood cells.
Export Options
About this article
Cite this article as:
Tomkowicz Brian and Ptasznik Andrzej, The Novel Role for Lyn in Integrin Signaling in Human Disease, Current Signal Transduction Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157436209787048685
DOI https://dx.doi.org/10.2174/157436209787048685 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine PARP Inhibitor Development for Systemic Cancer Targeting
Anti-Cancer Agents in Medicinal Chemistry Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions
Current Drug Targets Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Somatostatin and Octreotide on the Treatment of Acute Pancreatitis - Basic and Clinical Studies for Three Decades
Current Pharmaceutical Design T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells
Current Gene Therapy E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Current Cancer Therapy Reviews Inhibitors of ABL and the ABL-T315I Mutation
Current Topics in Medicinal Chemistry Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry The Role of Soluble 5'-Nucleotidases in the Conversion of Nucleotide Analogs: Metabolic and Therapeutic Aspects
Current Medicinal Chemistry MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis
Current Molecular Medicine